Podbit · Moonshots with Peter Diamandis
China just demonstrated the propulsive landing of an orbital booster for the first time — a milestone SpaceX reached years ago but that no other nation had managed. Against SpaceX's 580 total reflights and a single booster flown 36 times, China is years behind. But the monopoly on reusable heavy launch is now cracking.
Where this was said
At 48:20 · chapter starts 44:50
Peter reports that SpaceX has filed for 100,000 low-Earth orbit Starlink V3 spacecraft — up from the current 10,700 V2 satellites — with each V3 designed to support billions of AI-powered devices at multi-gigabit symmetrical throughput and extremely low latency. Starship Flight 13 is imminent, with Starship V3 booster and ship being tested. Dave Blundin, reflecting on recent podcast conversations with Will Marshall and Philip Johnston, argues that low Earth orbit is a scarce, self-cleaning resource — small objects are hit by solar wind, enter elliptical orbits, and eventually incinerate in the atmosphere. The US's infamous decision to launch 100,000 needles into orbit for radio reflection experiments took until 2026 to fully self-clean. Alex Wissner-Gross introduces the concept of very low Earth orbit (VLEO) satellites — so low they taste the atmosphere — which would look more like high-altitude balloons operating at orbital velocities, potentially air-breathing designs that could be kept aloft cheaply with periodic boosts [1] — Peter Diamandis "SpaceX filed for 100,000 LEO Starlink V3 satellites: SpaceX filed with regulators for 100,000 low-Earth orbit V3 Starlink spacecraft design…" 44:55 [2] — Peter Diamandis "China just demonstrated the propulsive landing of an orbital booster for the first time — a milestone SpaceX reached years ago but that no …" 48:20 .
SpaceX filed with regulators for 100,000 low-Earth orbit V3 Starlink spacecraft designed to support billions of AI-powered devices with multi-gigabit throughput.
Social norms compress behavior so effectively that we assume other minds are similar to ours. They almost never are. After running over 100 psychology studies, Greenberg's biggest finding is that humans are far more different from each other than we intuitively believe.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.